Inquiry Basket
Loading ......
Vesicular stomatitis virus (VSV) represents a significant viral pathogen affecting livestock throughout the Americas, causing sporadic yet economically devastating outbreaks in cattle, horses, and swine. As the prototype member of the Vesiculovirus genus within the Rhabdoviridae family, VSV has been extensively studied and serves as a model system for understanding negative-strand RNA virus replication. Beyond its veterinary importance, VSV possesses zoonotic potential, causing self-limiting influenza-like illness in humans, and has emerged as a valuable tool in biomedical research, particularly as a vaccine vector and oncolytic agent. This article provides a comprehensive examination of VSV biology, epidemiology, pathogenesis, clinical manifestations, and key molecular targets for therapeutic intervention.
Figure 1. Schematic diagram of the VSV virion. (Zhou K, et al. 2022)
VSV possesses a characteristic bullet-shaped virion, approximately 70 nm in diameter and 150–300 nm in length, composed of a lipid envelope derived from the host cell plasma membrane, a matrix protein layer, and a helical nucleocapsid. The viral envelope is studded with two transmembrane glycoproteins: the G protein, which mediates viral attachment and fusion with host cell membranes, and the small M2 protein, which modulates viral assembly and release. The matrix (M) protein lines the inner surface of the envelope, linking it to the nucleocapsid and playing critical roles in viral budding, host cell shutoff, and inhibition of host innate immune responses. The nucleocapsid consists of the viral genomic RNA tightly associated with the nucleoprotein (N), the phosphoprotein (P), and the RNA-dependent RNA polymerase (L), forming the functional ribonucleoprotein (RNP) complex that is responsible for viral RNA synthesis.
The VSV replication cycle is rapid and occurs entirely in the host cell cytoplasm, evading nuclear surveillance mechanisms. The cycle initiates with the binding of the viral G protein to cell surface receptors, which include low-density lipoprotein receptor (LDLR) family members and other uncharacterized receptors, followed by clathrin-mediated endocytosis. Acidification of the endosome triggers a conformational change in the G protein, leading to fusion of the viral and endosomal membranes and release of the RNP complex into the cytoplasm. Viral transcription is the first step in gene expression, with the L polymerase synthesizing five monocistronic mRNAs encoding the N, P, M, G, and L proteins in a strict sequential order, driven by the gradient of transcriptional start sites on the genomic RNA. Following sufficient accumulation of N, P, and L proteins, the polymerase switches from transcription to replication, generating full-length positive-sense antigenomic RNA, which serves as the template for synthesizing new negative-sense genomic RNA.
VSV exhibits an extremely broad host range, infecting most mammalian and some avian and reptilian species, a trait attributed to the widespread expression of its cell surface receptors and the virus’s ability to overcome host innate immune defenses in diverse species. In livestock, the primary clinical signs of VSV infection appear 2–5 days post-inoculation and include fever, anorexia, lethargy, and the formation of fluid-filled vesicles on the oral mucosa, lips, tongue, coronary bands of the hooves, and mammary glands. Vesicles eventually rupture, forming painful ulcers that lead to difficulty eating, drinking, and walking, resulting in weight loss, reduced milk production, and secondary bacterial infections. In severe cases, lameness may lead to recumbency, and neonatal animals may experience fatal systemic infection. While mortality is low in adult livestock, the economic impact is substantial due to reduced productivity and international trade bans on affected regions.
The pathogenesis of vesicular stomatitis virus involves intricate interactions between viral components and host cellular machinery, with several specific molecular targets emerging as critical determinants of infection outcome. Understanding these targets provides insights into disease mechanisms and identifies opportunities for therapeutic intervention.
| Key Molecular Targets | Details |
| IRF1 (Interferon Regulatory Factor 1) | IRF1 (Interferon Regulatory Factor 1) has been identified as a crucial transcription factor mediating antiviral defense against VSV in epithelial cells. Studies demonstrate that IRF1 deficiency renders cells highly susceptible to VSV infection through multiple mechanisms. |
| JAK-STAT | The JAK-STAT (Janus Kinase-Signal Transducer and Activator of Transcription) pathway, while essential for interferon signaling, appears dispensable for IRF1-mediated restriction of VSV in certain cell types. |
| The viral glycoprotein (G protein) | The viral glycoprotein (G protein) mediates receptor binding and membrane fusion. While the specific cellular receptor for VSV remains incompletely characterized, G protein interacts with cell surface molecules including phosphatidylserine receptors and LDLR (Low-Density Lipoprotein Receptor) family members. |
Beyond its role as a veterinary pathogen, VSV has become a highly versatile tool in molecular biology, virology, and translational medicine, due to its simple genome organization, rapid replication, broad tropism, and low pathogenicity in humans. As a model virus, VSV has been instrumental in elucidating the molecular mechanisms of negative-sense RNA virus replication, including transcription, replication, and viral assembly, and has provided insights into host-virus interactions and the innate immune response to viral infection. The VSV G protein is widely used in molecular biology to pseudotype other viruses, including lentiviruses and retroviruses, expanding their tropism and enabling efficient gene delivery into a broad range of cell types for gene therapy and research applications.
Vesicular stomatitis virus is a medically and veterinarily important pathogen with a broad host range and significant economic impact on the agricultural sector. Its unique biological properties, including a simple genome, rapid cytoplasmic replication, and ability to modulate host innate immune responses, have made it a classic model system for studying negative-strand RNA virus biology and host-virus interactions. The identification of key molecular targets in VSV pathogenesis, including TNF, JAK-STAT, IL-1, and IRF3/7, has not only advanced our understanding of how the virus evades host immunity and causes disease but also provided insights into the conserved mechanisms of innate immune defense against viral infection. Beyond its pathogenic role, VSV has emerged as a powerful biotechnological tool, with applications in gene delivery, oncolytic cancer therapy, and vaccine development for a wide range of human and animal diseases. As research into VSV continues, it is likely to yield further insights into viral replication and immunity, and to drive the development of novel therapeutics and vaccines to address both veterinary and human health challenges.
Reference
Loading ......
